Dolat Capital: Torrent Pharma Q2 Revenue In-Line With Estimates, Priced To Perfection
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
In Q2 FY21, Torrent Pharmaceuticals Ltd. reported muted performance in its key export markets – U.S. (20% YoY decline), Brazil (17% YoY decline, primarily due to currency depreciation) while India (7% YoY growth) aided in flattish revenues for the quarter, in-line with our estimates.
However, Ebitda margin at 31.5% were marginally better than expected led by controlled fixed costs.
With field activities resuming normalcy (approximately 75- 80% in both Indian and Brazilian market), we expect cost structure to normalise in next two quarters.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.